» Articles » PMID: 33523256

The Relevance of Multiple Sclerosis Cortical Lesions on Cortical Thinning and Their Clinical Impact As Assessed by 7.0-T MRI

Overview
Journal J Neurol
Specialty Neurology
Date 2021 Feb 1
PMID 33523256
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aimed to investigate at 7.0-T MRI a) the role of multiple sclerosis (MS) cortical lesions in cortical tissue loss b) their relation to neurological disability.

Methods: In 76 relapsing remitting and 26 secondary progressive MS patients (N = 102) and 56 healthy subjects 7.0-T T-weighted images were acquired for lesion segmentation; 3.0-T T-weighted structural scans for cortical surface reconstruction/cortical thickness estimation. Patients were dichotomized based on the median cortical lesion volume in low and high cortical lesion load groups that differed by age, MS phenotype and degree of neurological disability. Group differences in cortical thickness were tested on reconstructed cortical surface. Patients were evaluated clinically by means of the Expanded Disability Status Scale (EDSS).

Results: Cortical lesions were detected in 96% of patients. White matter lesion load was greater in the high than in the low cortical lesion load MS group (p = 0.01). Both MS groups disclosed clusters (prevalently parietal) of cortical thinning relative to healthy subjects, though these regions did not show the highest cortical lesion density, which predominantly involved frontal regions. Cortical thickness decreased on average by 0.37 mm, (p = 0.002) in MS patients for each unit standard deviation change in white matter lesion volume. The odds of having a higher EDSS were associated with cortical lesion volume (1.78, p = 0.01) and disease duration (1.15, p < 0.001).

Conclusion: Cortical thinning in MS is not directly related to cortical lesion load but rather with white matter lesion volume. Neurological disability in MS is better explained by cortical lesion volume assessment.

Citing Articles

Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.

Krijnen E, van Dam M, Bajrami A, Bouman P, Noteboom S, Barkhof F Ann Clin Transl Neurol. 2024; 12(1):121-136.

PMID: 39729590 PMC: 11752103. DOI: 10.1002/acn3.52261.


In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis.

Krijnen E, Lee H, Noteboom S, Chiang F, Steenwijk M, Schoonheim M Ann Clin Transl Neurol. 2024; 12(1):4-16.

PMID: 39673156 PMC: 11752088. DOI: 10.1002/acn3.52237.


Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis.

Mirmosayyeb O, Yazdan Panah M, Mokary Y, Mohammadi M, Moases Ghaffary E, Shaygannejad V PLoS One. 2024; 19(12):e0312421.

PMID: 39637162 PMC: 11620670. DOI: 10.1371/journal.pone.0312421.


Association of Levels of CSF Osteopontin With Cortical Atrophy and Disability in Early Multiple Sclerosis.

Marastoni D, Turano E, Tamanti A, Colato E, Pisani A, Scartezzini A Neurol Neuroimmunol Neuroinflamm. 2024; 11(5):e200265.

PMID: 38917380 PMC: 11203401. DOI: 10.1212/NXI.0000000000200265.


The impact of paramagnetic rim lesions on cortical thickness and gray to white matter contrast in relapsing-remitting multiple sclerosis.

Xie Y, Yao Y, Shen N, Li Y, Zhu H, Lu J Quant Imaging Med Surg. 2024; 14(3):2614-2626.

PMID: 38545072 PMC: 10963848. DOI: 10.21037/qims-23-1395.


References
1.
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J . New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017; 23(8):1123-1136. PMC: 5476197. DOI: 10.1177/1352458517694432. View

2.
Zhang Y, Salter A, Wallstrom E, Cutter G, Stuve O . Evolution of clinical trials in multiple sclerosis. Ther Adv Neurol Disord. 2019; 12:1756286419826547. PMC: 6391540. DOI: 10.1177/1756286419826547. View

3.
Sormani M, Bonzano L, Roccatagliata L, Cutter G, Mancardi G, Bruzzi P . Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009; 65(3):268-75. DOI: 10.1002/ana.21606. View

4.
Sormani M, Bruzzi P . MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013; 12(7):669-76. DOI: 10.1016/S1474-4422(13)70103-0. View

5.
Ontaneda D, Fox R . Imaging as an Outcome Measure in Multiple Sclerosis. Neurotherapeutics. 2016; 14(1):24-34. PMC: 5233623. DOI: 10.1007/s13311-016-0479-6. View